Bonello L, Laine M, Lemesle G, Puymirat E, Dabry T, Thuny F, et al. Meta-analysis of potent P2Y12-ADP receptor antagonist therapy compared to clopidogrel therapy in acute coronary syndrome patients with chronic kidney disease. Thromb Haemost. 2018;118:1839–46.
Mavrakanas TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G, et al. Duration of dual antiplatelet therapy in patients with CKD and drug-eluting stents: a meta-analysis. Clin J Am Soc Nephrol. 2019;14:810–22.
Article PubMed PubMed Central Google Scholar
Kao CC, Wu MS, Chuang MT, Lin YC, Huang CY, Chang WC, et al. Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease. PLoS ONE. 2021;16: e0255645.
Article CAS PubMed PubMed Central Google Scholar
National KF. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-266.
Kidney Disease: Improving Global Outcomes Blood Pressure Work G. Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;2021(99):S1–87.
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138:e618–51.
Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140:240–61.
Article PubMed PubMed Central Google Scholar
Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736–47.
Lambert PC. Flexible parametric survival analysis using Stata. College Station: STATA press; 2011. p. 1–339.
Lambert PC, Wilkes SR, Crowther MJ. Flexible parametric modelling of the cause-specific cumulative incidence function. Stat Med. 2017;36:1429–46.
Fujii T, Endo S, Tsuchiya R, Nagamatsu H, Kasai S, Kawamura Y, et al. Estimation of adverse events associated with P2Y12 receptor inhibitors stratified by academic research consortium for high bleeding risk criteria in acute coronary syndrome. Int J Cardiol. 2023. https://doi.org/10.1016/j.ijcard.2023.01.020.
Ndrepepa G, Lahu S, Aytekin A, Scalamogna M, Coughlan JJ, Gewalt S, et al. One-year ischemic and bleeding events according to renal function in patients with non-ST-segment elevation acute coronary syndromes treated with percutaneous coronary intervention and third-generation antiplatelet drugs. Am J Cardiol. 2022;176:15–23.
Article CAS PubMed Google Scholar
Wohrle J, Seeger J, Lahu S, Mayer K, Bernlochner I, Gewalt S, et al. Ticagrelor or prasugrel in patients with acute coronary syndrome in relation to estimated glomerular filtration rate. JACC Cardiovasc Interv. 2021;14:1857–66.
Hochholzer W, Wiviott SD, Antman EM, Contant CF, Guo J, Giugliano RP, et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation. 2011;123:2681–9.
Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360–420.
Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet (London, England). 2017;389:1025–34.
Fujii T, Ikari Y. Additional effect of hemodialysis on mortality estimated from renal function in ischemic heart disease. Future Cardiol. 2022;18:857–65.
Article CAS PubMed Google Scholar
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.
Article CAS PubMed Google Scholar
Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J. 2014;78:1684–92.
Comments (0)